Anti-CD19 chimeric antigen receptor T-cell therapies - Wuhan Bio Raid Biotechnology

Drug Profile

Anti-CD19 chimeric antigen receptor T-cell therapies - Wuhan Bio Raid Biotechnology

Alternative Names: anti-CD19 CAR-T therapy

Latest Information Update: 22 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Wuhan Bio-Raid Biotechnology
  • Developer Tongji Hospital; Wuhan Bio-Raid Biotechnology
  • Class CAR-T cell therapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown B cell lymphoma; Multiple myeloma

Most Recent Events

  • 14 Nov 2016 Clinical trials in B-cell lymphoma (Second-line therapy or greater, Refractory metastatic disease) in China (unspecified route) (ChiCTR-OPN-16009847)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top